WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) today announced it will report fourth quarter and year-end 2017 financial results on Tuesday, February 13, 2018, after the market closes. The press release will be available in the “Investor Relations” section of the company’s website at investors.bioverativ.com .
On Wednesday, February 14, 2018, at 8:00 a.m. EST, the company will host a live webcast with Bioverativ management. To access the live webcast, please visit Bioverativ’s Investors page at investors.bioverativ.com . An archived version of the webcast will be available following the presentation.
About Bioverativ
Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.
 //www.businesswire.com/news/home/20180116006152/en/
INVESTOR CONTACT:
Bioverativ Inc.
Sam Chase, +1 781-663-9277
IR@bioverativ.com
Source: Bioverativ Inc.